Abstract
Introduction
Urinary tract infections (UTIs) include infections of the kidneys, ureters,
and bladder. Escherichia coli is the major UTI pathogen, with emerging
extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly
difficult to treat. Bacterial resistance to the most commonly used UTI drugs
is growing, highlighting the unmet need and opportunity for novel therapies.
Scope of this research
- Disease background, segmentation and epidemiology of UTIs in the US, Japan
and five major European countries
- Overview of unmet needs, current clinical practice, guidelines and
adherence
- Discussion of trends in incidence of major pathogens and therapies as well
as resistance rates
- Outline of diagnosis, treatment and referral patterns
Research and analysis highlights
UTIs are a major driver of ambulatory care utilization. US statistics point to
more than 10 million visits to ambulatory care settings for UTIs per year.
From 1995 to 2006, the incidence of cystitis and UTI in unspecified sites in
the US increased by 10.7%.
Bacterial resistance is the most important factor affecting UTI treatment
options and varies both nationally and locally. Resistance rates as low as 10%
are deemed to be of concern with regards to efficacy of empiric therapy.
Levels of resistance to some older drugs may reach 40-50% in some areas,
rendering these drugs ineffective.
Two old drugs, nitrofurantoin and fosfomycin, have remarkably favorable
resistance profiles and good efficacy for the treatment of cystitis, and
therefore may provide highly useful future treatment options. Given these
compounds' age, they are not widely prescribed, requiring physician education
to improve familiarity and improve their uptake.
Key reasons to purchase this research
- Learn about the significance of UTIs as a an indication for antibacterial
compounds
- Understand and capitalize on clinical unmet needs in the market through
new product development in therapy and diagnosis
- Discover optimal ways to communicate with physicians by supporting efforts
to address gaps in diagnosis, treatment and guideline adherence
| 
View Cart
